Berotralstat

Contraindicated

Berotralstat Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details

Major

Berotralstat Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Berotralstat Clindamycin ANTIROBE Explained Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Relugolix Orgovyx Explained Increased relugolix exposure Details Berotralstat Abemaciclib Verzenio Explained Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Acalabrutinib Calquence Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Aliskiren Tekturna Increased P-gp substrate exposure Details Berotralstat Apixaban Eliquis Explained Increased P-gp substrate exposure Details Berotralstat Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Berotralstat Betrixaban Bevyxxa® Increased P-gp substrate exposure Details Berotralstat Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Berotralstat Afatinib Gilotrif Increased P-gp substrate exposure Details Berotralstat Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Berotralstat Axitinib Inlyta Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Bedaquiline Sirturo Increased bedaquiline exposure Details Berotralstat Bosutinib Bosulif Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Brexpiprazole Rexulti Increased brexpiprazole exposure Details Berotralstat Brigatinib Alunbrig Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Budesonide Entocort Increased budesonide exposure Details Berotralstat Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Berotralstat Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Berotralstat Clindamycin Injection ANTIROBE Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Clindamycin Topical C/T/S® Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Clindamycin Vaginal Cleocin Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Cobimetinib Cotellic Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Cyclosporine Injection Atopica Increased CYP3A4/P-gp substrate exposure Details Berotralstat Cyclosporine Ophthalmic Cequa Increased CYP3A4/P-gp substrate exposure Details Berotralstat Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Berotralstat Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Berotralstat Darolutamide Nubeqa Increased P-gp substrate exposure Details Berotralstat Dasatinib Phyrago Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Digoxin Cardoxin® Increased P-gp substrate exposure Details Berotralstat Dihydroergotamine Injection DHE-45® Injection Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Dihydroergotamine Nasal Spray Migranal Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Docetaxel Beizray Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Docetaxel Injection Beizray Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Dofetilide Tikosyn Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Berotralstat Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Berotralstat Edoxaban Savaysa Increased P-gp substrate exposure Details Berotralstat Encorafenib Braftovi Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details